DCDaein Choi

Daein Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daein Choi has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering

    by Waqas A Malick, Daein Choi, Anne Langsted, Vera Bittner, Børge G Nordestgaard, Erik S G Stroes, Robert S Rosenson

    Low-density lipoprotein cholesterol (LDL-C) is the pre-eminent target for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Despite the expansive evidence supporting therapeutic reductions in LDL-C with statin therapy, many high-risk patients do not achieve guideline-recommended treatment targets resulting in avoidable cardiovascular events and higher healthcare expenditures. Underutilization of effective LDL-C lowering is exacerbated by low adherence to statin therapy even among patients following an acute coronary event. Adjunctive therapies such as ezetimibe and PCSK9 monoclonal antibodies remain underutilized, and polypharmacy regimens used for the treatment of cardiovascular disease further increase challenges for patients. Although cardiovascular outcomes data are lacking, inclisiran, a small-interfering RNA (siRNA) targeting PCSK9 mRNA, is available for clinical use. Novel implementation approaches offer the opportunity for more durable or even potentially permanent solutions for lipoprotein-associated cardiovascular disease risk. As an adjunct to statins, these novel approaches may offer more durable approaches for the prevention of ASCVD events. In this review, we discuss the challenges of current LDL-C lowering therapies, achieving LDL-C targets and the necessity of novel approaches.


  • Open Access

    Combined Effects of Air Pollution and Changes in Physical Activity With Cardiovascular Disease in Patients With Dyslipidemia

    by Hye Jun Kim, Yun Hwan Oh, Sun Jae Park, Jihun Song, Kyuwoong Kim, Daein Choi, Seogsong Jeong, Sang Min Park

    Background: Sedentary behavior elevates cardiovascular disease (CVD) risk in patients with dyslipidemia. Increasing physical activity (PA) is recommended alongside pharmacological therapy to prevent CVD, though benefits across environmental conditions are unclear. Methods and Results: We analyzed data from 113 918 newly diagnosed patients with dyslipidemia (2009–2012) without prior CVD, sourced from the Korea National Health Insurance Service. Ambient particulate matter (PM) 2.5 and PM 10 levels were collected from the National Ambient Air Monitoring System in South Korea. Changes in PA, measured in metabolic equivalents of task–min/wk before and after dyslipidemia diagnosis, were evaluated for associations with air pollution levels and CVD risk using Cox proportional hazards regression. Patients were followed from January 1, 2013, until CVD onset, death, or December 31, 2021. Among patients exposed to low to moderate PM 2.5 levels (≤25 μg/m 3 ), increasing PA from inactive to ≥1000 metabolic equivalents of tasks–min/wk was associated with a lower risk of CVD (adjusted hazard ratio, 0.82 [95% CI, 0.70–0.97]; P for trend=0.022). In high PM 2.5 (>25 μg/m 3 ) conditions, increasing PA from inactive and decreasing PA from ≥1000 metabolic equivalents of task–min/wk was associated with reduced ( P for trend=0.010) and elevated ( P for trend=0.028) CVD risks, respectively. For PM 10 , increased PA was linked to reduced CVD risk ( P for trend=0.002) and decreased PA to elevated risk ( P for trend=0.042) in low to moderate PM 10 (≤50 μg/m 3 ) conditions, though benefits diminished at high PM 10 (>50 μg/m 3 ) exposures. Conclusions: Promoting PA, while considering the high potential cardiovascular risk associated with air pollution, may be an effective intervention against CVD in patients with dyslipidemia.


  • Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19

    by Daein Choi, Ori Waksman, Aleesha Shaik, Phyu Mar, Qinzhong Chen, Daniel J. Cho, HyoungSup Kim, Robin L. Smith, Sascha N. Goonewardena, Robert S. Rosenson


  • Open Access

    Combined Associations of Physical Activity and Particulate Matter With Subsequent Cardiovascular Disease Risk Among 5‐Year Cancer Survivors

    by Daein Choi, Seulggie Choi, Kyae Hyung Kim, Kyuwoong Kim, Jooyoung Chang, Sung Min Kim, Seong Rae Kim, Yoosun Cho, Gyeongsil Lee, Joung Sik Son, et al.

    Background: The combined associations of physical activity and particulate matter (PM) with subsequent cardiovascular disease (CVD) risk is yet unclear. Methods and Results: The study population consisted of 18 846 cancer survivors who survived for at least 5 years after initial cancer diagnosis from the Korean National Health Insurance Service database. Average PM levels for 4 years were determined in administrative district areas, and moderate‐to‐vigorous physical activity (MVPA) information was acquired from health examination questionnaires. A multivariable Cox proportional hazards model was used to evaluate the risk for CVD. Among patients with low PM with particles ≤2.5 µm (PM2.5; (19.8–25.6 μg/m 3 ) exposure, ≥5 times per week of MVPA was associated with lower CVD risk (adjusted hazard ratio [aHR], 0.77; 95% CI, 0.60–0.99) compared with 0 times per week of MVPA. Also, a higher level of MVPA frequency was associated with lower CVD risk ( P for trend=0.028) among cancer survivors who were exposed to low PM2.5 levels. In contrast, ≥5 times per week of MVPA among patients with high PM2.5 (25.8–33.8 μg/m 3 ) exposure was not associated with lower CVD risk (aHR, 0.98; 95% CI, 0.79–1.21). Compared with patients with low PM2.5 and MVPA ≥3 times per week, low PM2.5 and MVPA ≤2 times per week (aHR, 1.26; 95% CI, 1.03–1.55), high PM2.5 and MVPA ≥3 times per week (aHR, 1.34; 95% CI, 1.07–1.67), and high PM2.5 and MVPA ≤2 times per week (aHR, 1.38; 95% CI, 1.12–1.70) was associated with higher CVD risk. Conclusions: Cancer survivors who engaged in MVPA ≥5 times per week benefited from lower CVD risk upon low PM2.5 exposure. High levels of PM2.5 exposure may attenuate the risk‐reducing effects of MVPA on the risk of CVD.


  • Open Access

    Association of Rosacea With Cardiovascular Disease: A Retrospective Cohort Study

    by Daein Choi, Sungjun Choi, Seulggie Choi, Sang Min Park, Hyun‐Sun Yoon

    Background: There is emerging evidence that rosacea, a chronic cutaneous inflammatory disease, is associated with various systemic diseases. However, its association with cardiovascular disease (CVD) remains controversial. We aimed to investigate whether patients with rosacea are at increased risk of developing CVD. Methods and Results: This retrospective cohort study from the Korean National Health Insurance Service‐Health Screening Cohort included patients with newly diagnosed rosacea (n=2681) and age‐, sex‐, and index year–matched reference populations without rosacea (n=26 810) between 2003 and 2014. The primary outcome was subsequent CVD including coronary heart disease and stroke. Multivariable Cox regression analyses were used to evaluate adjusted hazard ratios for subsequent CVD adjusted for major risk factors of CVD. Compared with the reference population (13 410 women; mean [SD] age, 57.7 [9.2] years), patients with rosacea (1341 women; mean [SD] age, 57.7 [9.2] years) displayed an increased risk for CVD (adjusted hazard ratios, 1.20; 95% CI, 1.03–1.40) and coronary heart disease (adjusted hazard ratios, 1.29; 95% CI, 1.05–1.60). The risk for stroke was not significantly elevated (adjusted hazard ratios, 1.12; 95% CI, 0.91–1.37). Conclusions: This study suggests that patients with rosacea are more likely to develop subsequent CVD. Proper education for patients with rosacea to manage other modifiable risk factors of CVD along with rosacea is needed.


  • The Association of 5α-Reductase Inhibitor With Suicidality

    by Jihoon A. Kim, Daein Choi, Seulggie Choi, Jooyoung Chang, Sang Min Park

    Objective: Using a large nationwide cohort, this study aimed to determine the risk of suicide after the use of a 5α-reductase inhibitor, an antiandrogenic medication commonly used in the treatment of lower urinary tract symptoms. Methods: A retrospective population-based cohort study was performed using the Korean National Health Insurance Service database. The study consisted of 51,466 men 60 years or older who underwent health examinations between 2005 and 2006. Individuals using a 5α-reductase inhibitor were compared with nonusers based on drug exposure between 2003 and 2006. Individuals using a 5α-reductase inhibitor were additionally divided into tertiles based on cumulative 5α-reductase inhibitor exposure. The incidence of completed suicide was documented during 7 years of follow-up, starting January 1, 2007. Results: No significant risk of suicide was observed among 5α-reductase inhibitor users compared with 5α-reductase inhibitor nonusers (hazard ratio = 1.02, 95% confidence interval = 0.70–1.48). Cumulative 5α-reductase inhibitor exposure was also not associated with increased risk of suicide (p for trend = .543). Conclusions: 5α-Reductase inhibitor use was not associated with an elevated risk of suicide during a long-term follow-up period. A limitation of this study is that possible drug exposure after the index date was not accounted for. Although 5α-reductase inhibitor may increase the risk of depressive symptoms, the present data indicate that the drug is safe in terms of long-term suicide risk.


  • Exposure to oral bisphosphonates and risk of gastrointestinal cancer

    by D. Choi, S. Choi, J. Chang, S. M. Park

    Few studies have explored the association of oral bisphosphonate exposure and gastrointestinal cancer within Asian populations. In this study, we investigated 45,397 Korean women from the nationwide population-based cohort from 2002 to 2013. Oral bisphosphonate exposure did not appear to be associated with elevated or reduced risk for gastrointestinal cancer.


  • Open Access

    Pre-existing Depression among Newly Diagnosed Dyslipidemia Patients and Cardiovascular Disease Risk

    by Jihoon Andrew Kim, Seulggie Choi, Daein Choi, Sang Min Park

    Kim JA, et al. Diabetes Metab J. 2019 Jan;43:e55. https://doi.org/10.4093/dmj.2019.0002


  • Open Access

    Impact of Discrepancies in General and Abdominal Obesity on Major Adverse Cardiac Events

    by Daein Choi, Seulggie Choi, Joung Sik Son, Sang Woo Oh, Sang Min Park

    Background: Body mass index and waist circumference ( WC ) are commonly used metrics that reflect general obesity and abdominal obesity. However, the impact of general and abdominal obesity discrepancies on the risk for major adverse cardiac events ( MACE ) is less explored. Methods and Results: The study population was derived from the Korean National Health Insurance Service‐Health Screening Cohort. Among 315 982 participants aged 40 years or older who underwent health examinations between 2008 and 2009, body mass index and WC were used to determine the obesity status. The participants were followed from January 1, 2010 for MACE until December 31, 2015. Cox proportional hazards models were used to evaluate the association of obesity and the risk of MACE . Compared with men who were not obese, those with abdominal obesity without general obesity (adjusted hazard ratio ( aHR ) 1.29, 95% CI 1.16–1.43), and general and abdominal obesity ( aHR 1.20, 95% CI 1.12–1.29) had elevated risk of MACE , while those with general obesity without abdominal obesity ( aHR 1.06, 95% CI 0.98–1.16) did not. Similarly, women with abdominal obesity without general obesity ( aHR 1.13, 95% CI 1.03–1.24) and those with general and abdominal obesity ( aHR 1.15, 95% CI 1.06–1.25) had increased risk of MACE , while those with general obesity without abdominal obesity ( aHR 1.07, 95% CI 0.88–1.30) did not. Conclusions: Abdominal obesity without general obesity was associated with an elevated risk of major cardiovascular outcomes while general obesity without abdominal obesity did not. Concurrent determination of body mass index and WC may be beneficial for the accurate determination of future cardiovascular risk.


  • Open Access

    Impact of weight variability on mortality among Korean men and women: a population based study

    by Daein Choi, Seulggie Choi, Sang Min Park

    The health consequences of weight fluctuation have been controversial and little-studied within Asian populations. We aimed to determine the effect of weight variability on mortality using Korean National Health Insurance Service – National Health Screening Cohort. Weight variability was defined as the average successive variability of body mass index (BMI) of the first (2002 and 2003), second (2004 and 2005), and third (2006 and 2007) health examinations. Then, we used Cox regression models to estimate the effect of weight variability on mortality. Compared to participants within the first quintile (lowest) of weight variability, those within the fifth quintile (highest) had increased the risk of death from all causes (hazard ratio, HR 1.33, 95% confidence interval, CI 1.26–1.41), cardiovascular disease (HR 1.31, 95% CI 1.12–1.53), cancer (HR 1.11, 95% CI 1.02–1.22), and other causes (HR 1.58, 95% CI 1.45–1.73). The risk-increasing effect of weight variability on mortality was preserved after excluding past and current smokers as well as those with pre-existing cardiovascular disease or cancer. In conclusion, high weight variability may lead to elevated risk of death even among healthy never smokers. Therefore, maintaining a steady weight should be recommended to benefit from reduced risk of death.